• Veratridine in Chamber-Specific Cardiomyocyte Research

  2026-07-14

  Explore how Veratridine, a potent voltage-gated sodium channel opener, is reshaping chamber-specific cardiomyocyte modeling and sodium channel dynamics research. This article delivers unique insights into protocol design and translational applications beyond existing guides.

• ω-Agatoxin IVA TFA: Precision Tools for Synaptic Transmissio

  2026-07-14

  ω-Agatoxin IVA TFA enables selective P/Q-type calcium channel inhibition, unlocking high-resolution synaptic transmission and epilepsy model workflows. Its nanomolar potency and specificity streamline neuroprotection studies, making it an essential tool for neuroscience research.

• METTL14-m6A-lncRNA Axis: Epigenetic Regulation in Ulcerative

  2026-07-13

  This study uncovers how METTL14-mediated m6A RNA methylation modulates inflammation in ulcerative colitis through a lncRNA–miRNA–receptor pathway. The findings provide mechanistic insight into m6A-dependent epigenetic regulation in intestinal inflammation, supporting future research into targeted therapies for inflammatory bowel disease.

• Masitinib (AB1010): Technical Use in KIT/PDGFR Research Work

  2026-07-13

  Masitinib (AB1010) is a selective tyrosine kinase inhibitor designed for research requiring targeted inhibition of KIT, PDGFRα, and PDGFRβ signaling. It is best suited for DMSO-based workflows in cancer, mastocytosis, and inflammatory disease models, but is incompatible with aqueous or ethanol-based protocols and should not be used where broad-spectrum kinase inhibition is required.

• 2-D08 (2’,3’,4’-trihydroxyflavone): Precision Sumoylation In

  2026-07-12

  2-D08 (2’,3’,4’-trihydroxyflavone) is a uniquely selective inhibitor of protein sumoylation, enabling targeted disruption of SUMOylation without off-target effects on ubiquitination. Its application streamlines posttranslational modification studies in cancer and mitochondrial biology, offering researchers a powerful tool for mechanistic dissection and disease modeling.

• Antidepressant Properties of Rotigotine in Preclinical Model

  2026-07-10

  This study rigorously evaluates the antidepressant effects of rotigotine, a dopamine D2/D3 receptor agonist, across multiple validated rodent models of depression. The findings reveal dose-dependent behavioral improvements, supporting rotigotine's relevance for Parkinson's disease research addressing both motor and non-motor symptoms.

• Mc-Val-Cit-PABC-PNP: Technical Guide for ADC Linker Use

  2026-07-09

  Mc-Val-Cit-PABC-PNP is a cathepsin B-cleavable ADC peptide linker designed for targeted antibody-drug conjugate (ADC) synthesis, enabling controlled cytotoxic payload release upon lysosomal cleavage. It is optimized for organic solvent-based workflows and not suitable for aqueous, diagnostic, or therapeutic applications. Researchers should follow best practices for storage, solubilization, and workflow integration to ensure reliable results.

• SmD2 Acetylation Modulates Splicing and PARP Inhibitor Sensi

  2026-07-09

  This study elucidates how acetylation-dependent regulation of the core spliceosome protein SmD2 alters alternative splicing and DNA repair in hepatocellular carcinoma (HCC). The findings reveal that modulating SmD2 stability sensitizes HCC cells to PARP inhibitors, highlighting a novel combinatorial therapeutic strategy for BRCA-proficient tumors.

• Macrophage Mertk Drives Heart Failure via Type I IFN in Pres

  2026-07-08

  The reference study uncovers a mechanistic link between macrophage Mertk-mediated efferocytosis and the exacerbation of pressure overload-induced heart failure through a type I interferon pathway. These findings illuminate the role of Mertk in cardiac remodeling and suggest IFN-β as a critical downstream effector, with implications for targeted research on heart failure pathogenesis.

• Rotigotine: Dopamine D2/D3 Agonist Workflows in PD Research

  2026-07-08

  Rotigotine stands out as a versatile dopamine D2/D3 receptor agonist, enabling high-fidelity modeling of Parkinson’s disease in both cellular and animal systems. This article details protocol enhancements, innovative delivery strategies, and troubleshooting advice rooted in cutting-edge research, empowering scientists to unlock Rotigotine’s full potential in neurodegeneration assays.

• Optimizing Drug Conjugation with Gly-Gly-Phe-Gly (GGFG) Pept

  2026-07-07

  Gly-Gly-Phe-Gly (GGFG) serves as a versatile, high-purity peptide linker, driving next-generation bioconjugation in drug delivery and antibody-drug conjugate development. This article details advanced workflows, troubleshooting strategies, and practical insights to maximize GGFG’s value in translational research.

• Dihydroethidium: Precision Superoxide Detection in Live Cell

  2026-07-07

  Dihydroethidium (DHE, hydroethidine) is the gold-standard probe for quantifying intracellular superoxide, empowering oxidative stress assays in cardiovascular and apoptosis research. Optimized workflows and troubleshooting insights from recent studies ensure reproducibility and translational value for complex disease modeling.

• Rotigotine Hydrochloride: Advancing Translational PD Researc

  2026-07-06

  This thought-leadership article explores the multifaceted utility of Rotigotine hydrochloride as a dopamine D2/D3 receptor agonist in translational neuroscience. Integrating mechanistic insights, workflow guidance, and the latest analytical challenges, it provides a strategic roadmap for researchers modeling Parkinson's disease, restless legs syndrome, and related neurodegenerative conditions. Emphasis is placed on experimental rigor, product quality, and the translational bridge from bench to clinic, with actionable guidance for maximizing the scientific value of APExBIO's Rotigotine hydrochloride.

• Cycloastragenol Counters Bone Loss in Glucocorticoid-Induced

  2026-07-06

  This in vivo study demonstrates that cycloastragenol (CAG) effectively prevents bone loss by inhibiting osteoclast activity in a rat model of glucocorticoid-induced osteonecrosis of the femoral head (GIONFH) caused by methylprednisolone. The findings highlight osteoclast suppression as a key mechanism and provide translational insight for hip preservation strategies in patients exposed to synthetic glucocorticoid receptor agonists.

• LG 101506 (RXR modulator): Reliable RXR Signaling Tools for

  2026-07-05

  This article offers a scenario-driven, evidence-based exploration of how LG 101506 (RXR modulator, SKU B7414) empowers life science researchers to dissect nuclear receptor signaling, optimize cell-based immunoassays, and enhance reproducibility in immune-cold tumor models. It addresses real laboratory challenges, emphasizing validated solutions and protocol guidance for RXR pathway studies.

445 records 11/30 page Previous Next First page 上5页 1112131415 下5页 Last page